Latest news about Indraprastha Medical Corporation
Indraprastha Medical Corporation
371.90
+2.20(+0.60%)
Company Performance:
View Company Insights1D+0.60%
1M-0.64%
6M-9.03%
1Y-20.78%
5Y+408.76%
More news about Indraprastha Medical Corporation
07Apr 26
Indraprastha Medical Corporation Submits Quarterly Dematerialisation Compliance Certificate
Indraprastha Medical Corporation Limited submitted its quarterly dematerialisation compliance certificate for the quarter ended 31st March 2026 to BSE and NSE on 7th April 2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms adherence to SEBI Regulation 74(5) requirements. The filing demonstrates the healthcare company's commitment to regulatory compliance and transparency in securities operations.
01Apr 26
Indraprastha Medical Corporation Announces Completion of Independent Director Vinayak Chatterjee's Tenure
Indraprastha Medical Corporation Limited announced the completion of Mr. Vinayak Chatterjee's tenure as Independent Director on March 31, 2026. He completed his second five-year term on the Board of Directors and ceased to be a Director and Member/Chairperson of respective Board Committees. The company has provided required disclosures to stock exchanges under SEBI regulations.
21Mar 26
Indraprastha Medical Corporation Shareholders Approve Independent Director Appointments Through Postal Ballot
Indraprastha Medical Corporation Limited successfully completed its postal ballot voting on 20th March, 2026, with shareholders approving all four special resolutions for independent director appointments and re-appointments. The remote e-voting process saw 455 members vote representing 2,33,83,859 shares, with approval rates ranging from 94.09% to 99.94% across the four resolutions. The results strengthen the company's board composition with experienced independent directors for five-year terms.
18Feb 26
Indraprastha Medical Corporation Limited Announces Postal Ballot for Independent Directors' Appointment
Indraprastha Medical Corporation Limited has issued a postal ballot notice for shareholder approval of Independent Director appointments. The e-voting process runs from February 19 to March 20, 2026, covering re-appointment of three existing Independent Directors for second five-year terms and appointment of one new Independent Director. All resolutions require special resolution approval through NSDL's e-voting platform.
04Feb 26
Indraprastha Medical Corporation Reports Q3FY26 Financial Results with Strong Performance
Indraprastha Medical Corporation Limited reported Q3FY26 revenue of ₹378.76 crore and net profit of ₹41.00 crore, showing growth from the previous year. Nine-month revenue reached ₹1159.12 crore with net profit of ₹141.92 crore. The company maintained stable operations with EPS of ₹4.47 for the quarter and ₹15.48 for nine months, reflecting consistent performance in the healthcare sector.
01Nov 25
Indraprastha Medical Corp Reports Revenue Growth to Rs 3.8B in Q2
Indraprastha Medical Corporation Limited, operating Indraprastha Apollo Hospitals, has reported significant financial growth in Q2. Revenue increased to ₹3.80 billion from ₹3.50 billion year-over-year. EBITDA rose to ₹713.00 million from ₹636.00 million, with an improved EBITDA margin of 18.72%. Net profit grew by 16.60% to ₹494.60 crore. The company's Board of Directors approved these unaudited financial results in a recent meeting.
08Oct 25
Indraprastha Medical Shares Soar to All-Time High on CGHS Tariff Revision
Indraprastha Medical Corporation's shares have reached an all-time high of Rs 624.00, driven by a significant revision in Central Government Health Services (CGHS) tariffs. The stock has gained over 30% in 2 days, nearly 40% in 5 days, and 44% over the past 12 months. The CGHS has announced its largest tariff revision in 15 years, increasing rates by 5-30% for nearly 2,000 medical procedures. This is expected to positively impact the company's financials, particularly in specialties like Orthopaedics, Cardiology, and Oncology. However, the stock's RSI of 82.00 suggests potential overbought conditions.
06Aug 25
Indraprastha Medical Corp Reports Robust Q1 Performance with 15% Net Profit Growth
Indraprastha Medical Corporation Limited, operating as Indraprastha Apollo Hospitals, announced robust Q1 results. EBITDA increased to ₹726.00 million from ₹680.00 million year-over-year, with EBITDA margin rising to 19.89%. Net profit grew by 15% to ₹515.00 million, and revenue rose to ₹3.70 billion. The company reported a 4.94% increase in revenue from operations and a 14.94% increase in profit after tax. The Board of Directors made key corporate governance decisions, including new appointments and scheduling the 37th Annual General Meeting.
16May 25
Indraprastha Medical Corp Reports Strong Q4 Results, Declares Dividend
Indraprastha Medical Corp announced impressive Q4 financial results with EBITDA rising to ₹615.00 million from ₹484.00 million year-over-year. Net profit increased to ₹410.00 million, up 31.41% YoY. Revenue grew by 5.10% to ₹3.30 billion. The company declared a dividend of ₹4.50 per equity share. Annual performance showed significant growth with revenue up 13.79%, EBITDA up 30.80%, and net profit up 44.02% YoY. EPS increased from ₹9.40 to ₹13.52, and operating profit margin improved to 15.53% from 13.72%.
Industry Peers
Apollo Hospitals
Max Healthcare Institute
Fortis Healthcare
Aster DM Quality Care
Narayana Hrudayalaya
Global Health
Krishna Institute of Medical Sciences
Dr. Agarwal's Health Care
Rainbow Childrens Medicare
Park Medi World
8,702.00
(+0.10%)
990.50
(-0.95%)
918.00
(+1.20%)
750.90
(-1.40%)
1,859.80
(+2.42%)
1,405.50
(-0.30%)
766.35
(-2.06%)
497.80
(-0.48%)
1,460.10
(+1.88%)
280.05
(+2.00%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
